NY-UPFLEX
20.12.2022 15:01:37 CET | Business Wire | Press release
Upflex, the premier provider of hybrid workspace solutions, is bringing yet another successful year of company growth to a close. This momentum — a testament to flex as a new workplace standard — includes a 400% increase in Upflex’s customer base. Global corporations such as Willis Towers Watson, HH Global, and Schneider Electric, as well as leading tech firms such as Snowflake, Alation and Gympass are among those that have chosen Upflex as their hybrid workspace partner. To serve a fast-growing global demand, Upflex has increased its employee headcount by more than 200% with new hires across 12 countries.
Upflex, which was founded in 2018 by CEO Christophe Garnier and CPO Ginger Dhaliwal, builds technology and solutions to connect companies, space providers, and brokers in one cooperative ecosystem for more manageable, more sustainable flexible work. This year, with flexible workspace options being more important than ever, the company’s platform and flex workspace usage data have been in high demand.
“Since Upflex’s inception, providing a more efficient, flexible, and sustainable way of working has been our core mission,” said Christophe Garnier, CEO and co-founder of Upflex. “In 2022, we have seen that companies across the world are embracing hybrid work, and that they need better solutions for adopting and managing it. We’ve also seen in recent months that enterprise companies are increasingly concerned with cost savings moving toward a potential economic recession, and I’m thrilled that Upflex can be part of the solution for these employers to create new workspace efficiencies that cut real estate costs, so they don’t have to cut their people.”
Earlier this year, Upflex grew its EMEA presence with the acquisition of WorkClub, a UK-based coworking space aggregator, and entered an exclusive, strategic global partnership with WeWork, adding hundreds of WeWork locations to Upflex’s network of thousands of bookable desks, meeting rooms, and private offices around the world. As the sole aggregator of WeWork inventory, Upflex and WeWork clients benefit from enhanced coverage and optionality in workspaces. In May, Upflex announced a $30 million Series A round led by WeWork, with participation from top strategic and venture funds, including Newmark, Cushman & Wakefield, Industry Ventures, Inertia Ventures and GPO Fund.
Other 2022 milestones for Upflex include:
- Being selected as a finalist in the most prestigious awards in proptech: CRETech’s Real Estate Tech Awards;
- Expanding from 74 to 120 countries, including China, Japan, Indonesia, and Brazil, and increasing the company’s presence from 875 to 1,250 cities;
- Expanding Upflex's global workspace network from 4,900 to 10,000 workspace locations and adding 325 operators reaching a total of 1,350 operators;
- Launching a major partnership with brokerage firm Newmark to power Optality, a white-labeled version of the Upflex app. This partnership expands upon Upflex’s impressive roster of brokerage partners, including Colliers.
- Expanding its White Label offering to global flex operators including the UK’s largest flex operator Landmark, to make booking and payment instant and seamless for all their users across nearly 50 locations in nine major UK cities;
- Partnering with Chief Brand Advisory (CBA) in October to launch a reimagined brand strategy, in tandem adding CBA’s Founder, Brad Kay, as an investor and advisor;
- Continuing its partnership with the non-profit Trees for the Future to plant a tree for every desk booked on its platform. So far, Upflex has planted over 20,000 trees, a significant impact on reducing global carbon emissions and supporting its core mission of sustainability.
“Upflex will continue to invest a tremendous amount of resources to advance the development of our best-in-class hybrid work technology,” said Ginger Dhaliwal, CPO and co-founder of Upflex. “As companies look to make more informed real estate decisions, the future of the evolving workplace lies in utilization data. With Upflex’s real-time employee analytics, companies are able to be proactive in their workplace planning as they work to build sustainable strategies that serve their business, their people, and the planet.”
About Upflex:
Upflex (upflex.com) is a workspace intelligence platform bringing together people, places, and data to deliver the right workplace strategies for forward-thinking companies and their employees, from startups to the Fortune 100. Founded in 2018 as a co-working aggregator and booking platform, the company recently raised $30MM in Series A funding, forged an exclusive partnership with WeWork, and is expanding its operations to strengthen its global network. Today, Upflex has evolved beyond an aggregator, connecting companies, space providers and brokers to create an ecosystem of flexible and sustainable workspace experiences. Upflex leverages technology, services, and insights to make finding and managing global workspaces simple, smarter, and more agile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
